| UHC UMR Medical and Drug | Lumvoa™ (Veligrotug-Vvze) and Tepezza® (Teprotumumab-Trbw) – Commercial and Individual Exchange Medical Benefit Drug Policy | 2026-10-01 |
| UHC UMR Medical and Drug | Luxturna® (Voretigene Neparvovec-Rzyl) – Commercial and Individual Exchange Medical Benefit Drug Policy | 2026-10-01 |
| UHC UMR Medical and Drug | Otarmeni™ (Lunsotogene Parvec-Cwha) – Commercial and Individual Exchange Medical Benefit Drug Policy | 2026-10-01 |
| UHC UMR Medical and Drug | Respiratory Interleukin-5 Inhibitor – Commercial and Individual Exchange Medical Benefit Drug Policy | 2026-10-01 |
| UHC UMR Medical and Drug | Sodium Hyaluronate – Commercial and Individual Exchange Medical Benefit Drug Policy | 2026-10-01 |
| UHC UMR Medical and Drug | Zolgensma® (Onasemnogene Abeparvovec-Xioi) – Commercial and Individual Exchange Medical Benefit Drug Policy | 2026-10-01 |
| UHC Commercial Medical & Drug | Buprenorphine (Brixadi® & Sublocade®) – Commercial and Individual Exchange Medical Benefit Drug Policy | 2026-10-01 |
| UHC Commercial Medical & Drug | Denosumab – Commercial and Individual Exchange Medical Benefit Drug Policy | 2026-10-01 |
| UHC Commercial Medical & Drug | Gamifant® (Emapalumab-Lzsg) – Commercial and Individual Exchange Medical Benefit Drug Policy | 2026-10-01 |
| UHC Commercial Medical & Drug | Long-Acting Injectable Antiretroviral Agents for HIV – Commercial and Individual Exchange Medical Benefit Drug Policy | 2026-10-01 |